Sellas Life Sciences Group Inc (SLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.52B
Last updated: Nov 17, 2026 at 4:44 PM ET
Sellas Life Sciences Group Inc (SLS) Statistics
Sellas Life Sciences Group (SLS) has a market cap of $1.52B and an enterprise value of $1.39B. Its share count is up 86.76% from a year earlier.
Total Valuation
Enterprise value is 8.85% below the market cap, as cash exceeds debt.
| Market Cap | $1.52B |
|---|---|
| Enterprise Value | $1.39B |
| Latest price (Nov 17, 2026) | $19.15 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 29.4x |
|---|---|
| P/TBV Ratio | 29.8x |
Price Statistics
The stock is up 1239.16% over 52 weeks and trades 73.93% above its 50-day average.
| Beta (1Y) | 1.76 |
|---|---|
| 52-Week Change | +1239.16% |
| 1-Month Change | +82.55% |
| 3-Month Change | +38.27% |
| 6-Month Change | +152.31% |
| 5-Year Change | +11.39% |
| Total Return (1Y) | +1239.16% |
| Total Return (5Y CAGR) | +22.77% |
| Return vs SPY (1Y) | +1092.84% |
| Max Drawdown (1Y) | -51.68% |
| Max Drawdown (3Y) | -58.52% |
| Sharpe Ratio (1Y) | 1.75 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $11.01 |
| 200-Day Average | $8.88 |
| 52-Week Range | $1.39 to $15.88 |
| RSI (14 Days) | 76.6 |
| Average Volume (20 Days) | 13.04M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 14.92x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 14.92x |
|---|---|
| Quick Ratio | 14.92x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -27.13% and return on assets is -25.35% over the last 12 months.
| Return on Equity (ROE) | -27.13% |
|---|---|
| Return on Assets (ROA) | -25.35% |
| ROIC (5Y Average) | -31.52% |
Scores
SLS has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$39.45M |
| Pretax Income | -$35.76M |
| Net Income | -$35.76M |
| Reported EPS (TTM) | -$0.20 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.42% of the $141.09M in total assets.
| Cash and Equivalents | $134.71M |
|---|---|
| Total Debt | $0 |
| Net Cash | $134.71M |
| Net Cash Per Share | $0.67 |
| Working Capital | $129.29M |
| Shareholder Equity | $131.81M |
| Book Value Per Share | $0.65 |
| Tangible Book Value | $129.89M |
| Tangible Book Per Share | $0.64 |
| Total Assets | $141.09M |
| Total Liabilities | $9.29M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$27.30M |
|---|---|
| FCF Per Share | -$0.14 |
| Depreciation and Amortization | $613.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
SLS does not pay a dividend.
| Buyback Yield | -0.75% |
|---|---|
| Shareholder Yield | -0.75% |
Stock Splits
The last split was a 1-for-50 reverse split on Nov 8, 2019.
| Last Split Date | Nov 8, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:50 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SLS
What is SLS's market cap?
Sellas Life Sciences Group has a market cap of $1.52B. Its enterprise value, which adds debt and subtracts cash, is $1.39B.
How many shares of SLS are outstanding?
Sellas Life Sciences Group has 202.44M shares outstanding. The count is up 86.76% from a year earlier.
Does SLS pay a dividend?
No. Sellas Life Sciences Group does not pay a dividend.
How much debt does SLS have?
Sellas Life Sciences Group has $0 of total debt and $134.71M of cash and equivalents, a net cash position of $134.71M.
SLS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors